Rodriguez Michelle M, Overshiner Carl, Leander J David, Li Xia, Morrow Denise, Conway Richard G, Nelson David L, Briner Karin, Witkin Jeffrey M
Neuroscience Discovery Research and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
Front Psychiatry. 2017 May 22;8:89. doi: 10.3389/fpsyt.2017.00089. eCollection 2017.
Selective serotonin reuptake inhibitors (SSRIs) are the only effective pharmacological treatments for obsessive-compulsive disorder (OCD). Nonetheless, their generally limited efficacy, side-effects, and delayed onset of action require improved medications for this highly prevalent disorder. Preclinical and clinical findings have suggested serotonin2C (5-HT) receptors as a potential drug target. Data in rats and mice are presented here on the effects of a novel 5-HT receptor agonist ((3S)-3-Methyl-1-[4-(trifluoromethyl)-7-benzofuranyl]-piperazine) (CPD 1) with high potency and full efficacy at 5-HT receptors and less potency and partial agonism at 5-HT and 5-HT receptors. Effects of CPD 1 on consummatory (schedule-induced polydipsia in rats) and non-consummatory behaviors (marble-burying and nestlet-shredding in mice) that are repetitive and non-habituating were studied. We also evaluated the effects of CPD 1 in rats with isoproterenol- and deprivation-induced drinking in rats to compare with the polydipsia studies. The SSRIs, fluoxetine, and chlomipramine decreased the high rates of drinking in rats engendered by a schedule of intermittent food delivery (schedule-induced polydipsia). The effects of fluoxetine, but not of d-amphetamine, were prevented by the selective 5-HT receptor antagonist SB242084. The 5-HT receptor agonists Ro 60-0175 and CPD 1 also decreased drinking, but unlike the SSRIs and Ro 60-0175, CPD 1 dose-dependently decreased excessive drinking without affecting lever press responses that produced food. The effects of CPD 1 were prevented by SB242084. CPD 1 also suppressed drinking induced by isoproterenol and by water deprivation without affecting normative drinking behavior. CPD 1, like fluoxetine, also suppressed marble-burying and nestlet-shredding in mice at doses that did not affect rotarod performance or locomotor activity. The behavioral specificity of effects of CPD 1 against repetitive and excessive behaviors suggests a potential therapeutic application in OCD.
选择性5-羟色胺再摄取抑制剂(SSRIs)是治疗强迫症(OCD)唯一有效的药物疗法。尽管如此,它们普遍疗效有限、有副作用且起效延迟,因此需要为这种高发性疾病研发更好的药物。临床前和临床研究结果表明5-羟色胺2C(5-HT)受体是一个潜在的药物靶点。本文给出了大鼠和小鼠实验数据,内容是关于一种新型5-HT受体激动剂((3S)-3-甲基-1-[4-(三氟甲基)-7-苯并呋喃基]-哌嗪)(CPD 1)的作用,它对5-HT受体具有高效能和完全激动效应,而对5-HT和5-HT受体的效能较低且具有部分激动作用。研究了CPD 1对重复性且无习惯性的进食行为(大鼠的定时诱导多饮)和非进食行为(小鼠的埋大理石和撕咬筑巢材料)的影响。我们还评估了CPD 1对异丙肾上腺素诱导和剥夺诱导的大鼠饮水的影响,以便与多饮研究进行比较。SSRIs、氟西汀和氯米帕明可降低间歇性喂食计划(定时诱导多饮)导致的大鼠高饮水率。选择性5-HT受体拮抗剂SB242084可阻断氟西汀而非右旋苯丙胺的作用。5-HT受体激动剂Ro 60-0175和CPD 1也可降低饮水,但与SSRIs和Ro 60-0175不同的是,CPD 1剂量依赖性地减少过度饮水,而不影响产生食物的杠杆按压反应。SB242084可阻断CPD 1的作用。CPD 1还可抑制异丙肾上腺素和缺水诱导的饮水,而不影响正常饮水行为。与氟西汀一样,CPD 1在不影响转棒试验表现或运动活性的剂量下,也可抑制小鼠的埋大理石和撕咬筑巢材料行为。CPD 1对重复性和过度行为的行为特异性效应表明其在强迫症治疗中具有潜在应用价值。